Thus, preclinical data showed that inhibition of CXCR4 by neutralizing antibodies, siRNAs, and antagonists such as AMD3100 (Plerixafor, Mozobil) and MSX-122 (Metastatix, phase I trial) can inhibit tumor growth and reduce metastasis [123,124]. Here, CXCR4 is linked to neoplasm.